Role of a Mutation in Human Cytomegalovirus Gene UL104 in Resistance to Benzimidazole Ribonucleosides

Journal of Virology

Volumn 78, Issue 2, 2004, Pages 710-715

  Komazin, Gloria ^a   Townsend, Leroy B ^a   Drach, John C ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (ALPHA DEXTRO 5 DEOXYLYXOFURANOSYL) 2,5,6 TRICHLOROBENZIMIDAZOLE; 1 (BETA DEXTRO RIBOFURANOSYL) 2 BROMO 5,6 DICHLOROBENZIMIDAZOLE; 1 (BETA DEXTRO RIBOFURANOSYL) 2,5,6 TRICHLOROBENZIMIDAZOLE; ANTIVIRUS AGENT; BENZIMIDAVIR; BENZIMIDAZOLE DERIVATIVE; GANCICLOVIR; RIBONUCLEOSIDE DERIVATIVE; TOMEGLOVIR; UMJD 1311; UNCLASSIFIED DRUG; VIRUS DNA;

AMINO ACID SUBSTITUTION; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA PACKAGING; DRUG BINDING SITE; DRUG SELECTIVITY; ENZYME SUBUNIT; GENE MUTATION; HUMAN; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN INTERACTION; UL104 GENE; UL56 GENE; UL89 GENE; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS INHIBITION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; WILD TYPE;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CAPSID PROTEINS; CELLS, CULTURED; CYTOMEGALOVIRUS; DRUG RESISTANCE, VIRAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; RIBONUCLEOSIDES; SEQUENCE ANALYSIS, DNA; VIRAL PROTEINS;

EID: 0346688644     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.2.710-715.2004     Document Type: Article

References (40)

1. Amin, H. I., E. Ai, H. R. McDonald, and R. N. Johnson. 2000. Retinal toxic effects associated with intravitreal fomivirsen. Arch. Ophthalmol. 118:426-427.
2. Bender, W., et al. December 2002. U.S. patent 6,498,183.
3. Bogner, E., K. Radsak, and M. F. Stinski. 1998. The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity. J. Virol. 72:2259-2264.
4. Borst, E. M., G. Hahn, U. H. Koszinowski, and M. Messerle. 1999. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J. Virol. 73:8320-8329.
5. Britt, W. J., R. F. Pass, S. Stagno, and C. A. Alford. 1991. Pediatric cytomegalovirus infection. Transplant. Proc. 23:115-117.
6. Buerger, I., J. Reefschlaeger, W. Bender, P. Eckenberg, A. Popp, O. Weber, S. Graeper, H. D. Klenk, H. Ruebsamen-Waigmann, and S. Hallenberger. 2001. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J. Virol. 75:9077-9086.
7. Chrisp, P., and S. P. Clissold. 1991. Foscarnet: a review of its antiviral activity, pharmacokinetic properties, and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41:104-129.
8. Crumpacker, C. S. 1996. Ganciclovir. Drug Ther. 335:721-729.
9. Curran, M., and S. Noble. 2001. Valganciclovir. Drugs 61:1145-1152.
10. Deray, G., F. Martinez, C. Katlama, B. Levaltier, H. Beaufils, M. Danis, M. Rozenheim, A. Baumelou, E. Dohin, M. Gentilini, and C. Jacobs. 1989. Foscarnet nephrotoxicity-mechanism, incidence and prevention. Am. J. Nephrol. 9:316-321.
11. Drocourt, D., T. Calmels, J. P. Reynes, M. Baron, and G. Tiraby. 1990. Cassettes of the Streptoalloteichus hindustanus ble gene for transformation of lower and higher eukaryotes to phleomycin resistance. Nucleic Acids Res. 18:4009.
12. Erice, A. 1999. Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbiol. Rev. 12:286-297.
13. Grattan, M. T., C. E. Moreno-Cabral, V. A. Starnes, E. B. Stinson, and N. E. Shumway. 1989. Cytomegalovirus infection is associated with cardiac allograph rejection and atherosclerosis. JAMA 261:3561-3566.
14. Hitchcock, M. J. M., H. S. Jaffe, J. C. Martin, and R. J. Stagg. 1996. Cidofovir, a new agent with potent anti-herpesvirus activity. Antivir. Chem. Chemother. 7:115-127.
15. Hobom, U., W. Brune, M. Messerle, G. Hahn, and U. H. Koszinowski. 2000. Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes. J. Virol. 74:7720-7729.
16. Komazin, G., R. G. Ptak, B. T. Emmer, L. B. Townsend, and J. C. Drach. 2003. Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. J. Virol. 77:11499-11506.
17. Koszalka, W. G., S. D. Chamberlain, R. J. Harvey, L. W. Frick, S. S. Good, M. L. Davis, A. Smith, K. K. Biron, J. C. Drach, and L. B. Townsend. 1996. Benzimidazoles for the treatment of human cytomegalovirus. Antivir. Res. 30:A43.
18. Krosky, P. M., M. R. Underwood, S. R. Turk, K. W.-H. Feng, R. K. Jain, R. G. Ptak, A. C. Westerman, K. K. Biron, L. B. Townsend, and J. C. Drach. 1998. Resistance of human cytomegalovirus to benzimidazole nucleoside analogs maps to two open reading frames: UL89 and UL56. J. Virol. 72:4721-4728.
19. Lamberti, C., and S. K. Weller. 1996. The herpes simplex virus type 1 UL6 protein is essential for cleavage and packaging but not for genomic inversion. Virology 226:403-407.
20. Lee, E. C., D. Yu, J. Martinez de Velasco, L. Tessarollo, D. A. Swing, D. L. Court, N. A. Jenkins, and N. G. Copeland. 2001. A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics 73:56-65.
21. McKenzie, R., M. W. D. Travis, S. A. Dolan, S. Pittaluga, I. M. Feuerstein, J. Shelhamer, R. Yarchoan, and H. Masur. 1991. The cause of death in patients with human immunodeficiency virus infection: a clinical and pathological study with emphasis on the role of pulmonary disease. Medicine 70:326-343.
22. Melnick, J. L., E. Adam, and M. E. DeBakey. 1998. The link between CMV and atherosclerosis. Infect. Med. 15:479-486.
23. Migawa, M. T., J. L. Girardet, J. A. Walker II, G. W. Koszalka, S. D. Chamberlain, J. C. Drach, and L. B. Townsend. 1998. Design, synthesis, and antiviral activity of α-nucleosides: D- and L-isomers of lyxofuranosyl- and (5-deoxylyxofuranosyl) benzimidazoles. J. Med. Chem. 41:1242-1251.
24. Newcomb, W. W., R. M. Juhas, D. R. Thomsen, F. L. Homa, A. D. Burch, S. K. Weller, and J. C. Brown. 2001. The UL6 gene product forms the portal for entry of DNA into the herpes simplex virus capsid. J. Virol. 75:10923-10932.
25. Pari, G. S., and D. G. Anders. 1993. Eleven loci encoding trans-acting factors are required for transient complementation of human cytomegalovirus ori-Lyt-dependent DNA replication. J. Virol. 67:6979-6988.
26. Perry, C. M., and J. A. Balfour. 1999. Fomivirsen. Drugs 57:375-380.
27. Prichard, M. N., S. R. Turk, L. A. Coleman, S. L. Englehardt, C. J. Shipman, and J. C. Drach. 1990. A microtiter virus yield reduction assay for the evaluation of antiviral compounds against human cytomegalovirus and herpes simplex virus. J. Virol. Methods 28:101-106.
28. Scheffczik, H., C. G. Savva, A. Holzenburg, L. Kolesnikova, and E. Bogner. 2002. The terminase subunits pUL56 and pUL89 of human cytomegalovirus are DNA-metabolizing proteins with toroidal structure. Nucleic Acids Res. 30:1695-1703.
29. Scholz, B., S. Rechter, J. C. Drach, L. B. Townsend, and E. Bogner. 2003. Identification of the ATP-binding site in the terminase subunit pUL56 of human cytomegalovirus. Nucleic Acids Res. 31:1426-1433.
30. Shipman, C. J. 1969. Evaluation of 4-(2-hydroxyethyl)-1-piperazineë thane-sulfonic acid (HEPES) as a tissue culture buffer. Proc. Soc. Exp. Biol. 130:305-310.
31. Townsend, L. B., R. V. Devivar, S. R. Turk, M. R. Nassiri, and J. C. Drach. 1995. Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(β-D-ribofuranosyl)benzimidazoles. J. Med. Chem. 38:4098-4105.
32. Turk, S. R., C. Shipman, R. Nassiri, G. Genzlinger, S. H. Krawczyk, L. B. Townsend, and J. C. Drach. 1987. Pyrrolo[2,3-d]pyrimidine nucleosides as inhibitors of human cytomegalovirus. Antimicrob. Agents Chemother. 31:544-550.
33. Underwood, M. R., R. J. Harvey, S. C. Stanat, M. L. Hemphill, T. Miller, J. C. Drach, L. B. Townsend, and K. K. Biron. 1998. Inhibition of human cytomegalovirus DNA maturation by a benzimidazole ribonucleoside is mediated through the UL89 gene product. J. Virol. 72:717-725.
34. van Zeijl, M., J. Fairhurst, T. R. Jones, S. K. Vernon, J. Morin, J. LaRocque, B. Feld, B. O'Hara, J. D. Bloom, and S. V. Johann. 2000. Novel class of thiourea compounds that inhibit herpes simplex virus type 1 DNA cleavage and encapsidation: resistance maps to the UL6 gene. J. Virol. 74:9054-9061.
35. Visalli, R. J., J. Fairhurst, S. Srinivas, W. Hu, B. Feld, M. DiGrandi, K. Curran, A. Ross, J. D. Bloom, M. van Zeijl, T. R. Jones, J. O'Connell, and J. I. Cohen. 2003. Identification of small molecule compounds that selectively inhibit varicella-zoster virus replication. J. Virol. 77:2349-2358.
36. White, C. A., N. D. Stow, A. H. Patel, M. Hughes, and V. G. Preston. 2003. Herpes simplex virus type 1 portal protein UL6 interacts with the putative terminase subunits UL15 and UL28. J. Virol. 77:6351-6358.
37. Wingard, J. R., S. Piantadosi, W. H. Burns, M. L. Zahurak, G. W. Santos, and R. Saral. 1990. Cytomegalovirus infections in bone marrow transplant recipients given intensive cytoreductive therapy. Rev. Infect. Dis. 12(Suppl. 7):S793-S804.
38. Yu, D., H. M. Ellis, E. C. Lee, N. A. Jenkins, N. G. Copeland, and D. L. Court. 2000. An efficient recombination system for chromosome engineering in Escherichia coli. Proc. Natl. Acad. Sci. USA 97:5978-5983.
39. Yu, D., and S. K. Weller. 1998. Herpes simplex virus type 1 cleavage and packaging proteins UL15 and UL28 are associated with B but not C capsids during packaging. J. Virol. 72:7428-7439.
40. Zhou, Y. F., M. B. Leon, M. A. Waclawiw, J. J. Popma, Z. X. Yu, T. Finkel, and S. E. Epstein. 1994. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N. Engl. J. Med. 335:624-630.